Eli Lilly Chairman & CEO David Ricks discusses GLP-1's, Alzheimer's, business development, and more
From the company's headquarters in Indianapolis, he describes where he thinks the obesity field could be headed in the next few years, what might be next after beta-amyloid in Alzheimer's, and how he plans to invest for the future.









.png)